August 7, 2023

Supplementary Documents of Consolidated
Financial Results for the First Quarter of the YearEnding March 31, 2024 (FY2023)

Stock code：4886 (TSE)
ASKA Pharmaceutical Holdings Co., Ltd.

Highlight
1Q FY2023 (Consolidated)✓ 16.0 billion yen, up 4.9% YOY
Net sales

Showed a favorable trend in the pharmaceutical business, despite the annual NHI drug price revision.

8.5 billion yen, up 6.8 percentage points YOY✓
Cost of sales
Increased 0.9 percentage points due to rising prices of raw materials and energy costs.
SG&A
expenses

Operatingprofit✓ 5.8 billion yen, up 3.1 percentage points YOY
Impacted by increases in business activity expenses and R&D expenses.

✓ 1.7 billion yen, up 2.4% YOY
Increased due to an increase in gross profit

FY2023 (Consolidated) – No changes from the forecast previously announced
Performance ✓ Net sales 62.0 billion yen, up 2.5% YOYforecast✓ Operating profit 5.4 billion yen, up 5.7% YOY
2

Statements of Income (Consolidated)(Millions of yen)

FY2022 Apr - JunActualFY2023 Apr - JunActualActual +/-Growth +/-Net sales15,269

16,023753

4.9%

Operating profit

1,664

1,704

39

2.4%

Ordinary profit

1,805

1,809

30.2%

Profit attributable toowners of parent

1,323

1,428

105

8.0%

Major factors for increases
 Despite the impact of higher raw materials and energy costs, the Group, mainly in the pharmaceuticalbusiness, also achieved increases in sales and profit from the same period of the previous year due to thegrowth of new products and continued cost-cutting efforts.

3

Net Sales by Business (Consolidated)(Millions of yen)

FY2022 Apr - JunActualFY2023 Apr - JunActualBreakdown

Actual +/-Growth +/-Pharmaceuticalbusiness

13,646

14,420

90.0%

773

5.7%

Animal healthbusiness

1,593

1,560

9.7%

-32-2.1%

29420.3%

1244.1%

15,26916,023100.0%

753

4.9%

Other businesses
Total

Major factors for increases/decreases
 The pharmaceuticals business remained strong overall despite the impact of the annual NHI drug price revisions. Sales of DroEthi, which
was launched in June 2022, increased significantly from the previous year to 1,401 million yen (up 240.1% YOY).
 In the animal health business, sales remained at the same level as the previous year, mainly of livestock pharmaceuticals and feed
additives.
 In the other business, which includes clinical testing and medical devices, sales of hair hormone level measurement kits also contributed
to sales. Net sales increased.

4Sales of Main Products (ASKA Pharmaceutical Co., Ltd.)
Area

Category

Internal Medicine

AG(candesartan)

THYRADIN

Brand-nameRIFXIMA

Brand-name

MERCAZOLE

Brand-name

Obstetrics and Gynecology

CANDESARTAN * 1

Brand-nameGenericUrology

Products(generic name)

Generic(levothyroxine)(rifaximin)(thiamazole)

AMLODIPINE(amlodipine)

RELUMINA(relugolix)

DroEthi(norethisterone/ethinylestradiol)AG

FREWELL

Brand-name

LUTEUM

Brand-name

ANGE

Brand-name

MAGSENT * 2

Generic(drospirenone/ethinylestradiol)(progesterone)(levonorgestrel/ethinylestradiol)(magnesium sulfate)

LEUPRORELIN * 3(leuprorelin)

FY2022
Apr - Jun
ActualFY2023Apr – Jun
ActualFY2023YOY

Forecast(Millions of yen)

Notes
YOY
The NHI drug price declined, but sales
volume remained

2,859

2,599

-9.1%

9,268

-13.6%

2,0402,062

1.1%

7,833

1.3%

Progress as expected

1,404

1,525

8.6%

5,578

3.4%

Sales grew steadily as the Guideline
penetrated

390

398

2.0%

1,513

1.8%

Progress as expected242

225-6.9%

844-6.3%

The NHI drug price declined, but sales
volume remained

2,259

2,576

14.0%

10,12814.6%

Progress as expected

412

1,401

240.1%

4,165

13.5%

Launched in June last year. Sales in AprilJune recorded in this fiscal year888

832-6.2%

3,407-2.4%

Sales volume increased, but sales areslightly lower than expected.

214

440

105.0%

1,363

8.9%

Increase due to effects of removing
shipping restrictions

228

194

-15.0%

799

1.9%

153

154

0.6％

750

19.6%

1,357

1,192

-12.2%

4,828

-3.4%

* 1 Including compounding agents* 3 1.88mg formulation is for gynecological indications only, but combined with 3.75mg formulation* 2 Total value of magnesium sulfate preparation

Decrease due to switch to other companies’
products
The NHI drug price increased, but weestimate the number of deliveries hasdecreased.
Switch to other products progressed morethan expected

5Sales by Major Business Field (ASKA Animal Health)(Millions of yen)

FY2022 Apr – J un

FY2023 Apr - Jun

FY2023Business field
ActualActualYOY

Forecast

YOY

Feed additives andmaterials, Mixed feed

1,041

965

-7.3%

3,832

-7.7%

Veterinary
pharmaceuticals

503

576

14.5%

2,490

5.1%

(livestock and fisheries + *CA)

Major factors for increases/decreases

 Sales of feed additives decreased due to softer market prices for feed additives.
 In veterinary pharmaceuticals, sales increased due to solid sales of the TRILOSTANE TABLETS“ASKA,” launched in November 2022, and other products.
* Companion Animal
6

Sales Proportion of Brand-name Drugs■ Brand-name drugs ■ Generic drugs
1Q FY2022

1Q FY2023

52.7%

53.0%

Despite significant growth in sales of DroEthi, a generic drug,
RELUMINA, RIFXIMA, and THYRADIN improved the product mix, resulting in a 0.3 percentage point increasein the ratio of brand-name drugs to sales.

7

R&D Status
As of August 7, 2023

Trend of R&D expenses（Millions of yen）
(Forecast)

4,227

4,3093,598

Development code (Generic name) / Indication

Phase

LF111 (drospirenone)
Contraception

Ph III(Option agreement)
Treatment for PMS/PMDD

Ph II(IIT *1)

AKP-022 (Relugolix combination tablet)
Uterine fibroids

Ph I / II*1 Investigator-initiated clinical trial

TRM-270 (adhesion barrier)(Gastroenterology and Ob/Gyn)

Ph III

L-105 (rifaximin)
Hepatic encephalopathy (pediatrics)

Filed

AKP-009 (ludaterone acetate)
Benign prostatic hyperplasia

Ph II

941
(1Q)

FY20212022年3月期

FY2022
2023年3月期

FY20232024年3月期

AKP-017（transnasal testosterone）(Urology)

Preparing forclinical trials- AKP-009 : Phase I trial is to be conducted again.

88